Docetaxel in the Treatment of Esophageal Cancer
Section snippets
Trials of Single-Agent Docetaxel
A number of phase II trials have evaluated the safety and efficacy of docetaxel as a single agent in the treatment of esophageal cancer (Table 1).22, 23, 24, 25, 26, 27 Docetaxel was administered intravenously (IV) once every 3 weeks in doses ranging from 6023 to 100 mg/m2,24, 25, 26 with prophylactic administration of 5 μg/kg granulocyte colony-stimulating factor (G-CSF) in one study.25 The most common grade III or IV toxicities included neutropenia, accompanied in some cases by fever.
Docetaxel-Based Combination Regimens for Metastatic or Advanced Disease
Docetaxel has been evaluated in combination with other chemotherapeutic agents for the treatment of esophageal cancer in the metastatic/advanced disease setting (Table 2). Although phase I trials included combinations with a multitude of chemotherapeutic agents (eg, gemcitabine, 5-FU, ifosfamide, lonafarnib, carboplatin, capecitabine, oblimersen, thalidomide),28, 29, 30, 32, 33, 34, 35, 36, 37, 55 phase II data for docetaxel-based combination chemotherapy for metastatic/advanced esophageal
Docetaxel-Based Neoadjuvant and Adjuvant Regimens
Neoadjuvant (induction) therapy before surgery may reduce tumor bulk and improve surgical response, especially in patients with locally advanced operable cancers, while adjuvant therapy may reduce the incidence of local recurrence and distant metastasis. Docetaxel has been evaluated as part of both neoadjuvant and adjuvant therapy (Table 4).44, 45
Summary
Phase I trials of docetaxel-based combination regimens with antimetabolites (gemcitabine, 5-FU), other chemotherapy agents (ifosfamide), and radiation therapy have been encouraging, with the establishment of the MTD in most of these regimens. Phase II trials of docetaxel-based combination regimens (5-FU, irinotecan) have shown antitumor activity in patients with previously treated or untreated esophageal cancer and manageable toxicity profiles. Furthermore, the combined-modality approach of
References (63)
Barrett’s esophagus and esophageal adenocarcinomaPathogenesis, diagnosis, and therapy
Med Clin North Am
(2002)The use of chemoradiotherapy in oesophageal cancer
Eur J Cancer
(2002)- et al.
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer
Ann Oncol
(2004) - et al.
A phase II study of weekly docetaxel and concurrent radiation in patients (pts) with unresectable esophageal cancer
Eur J Cancer
(2001) - et al.
Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo
Eur J Cancer
(1996) - et al.
Oesophageal cancer
Cancer Surv
(1994) - et al.
Cancer statistics, 2000
CA Cancer J Clin
(2000) - et al.
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995
Int J Cancer
(2002) - et al.
Neoplasms of the esophagus
- et al.
Chemotherapy in esophageal cancer
Semin Oncol
(1999)
Clinical Practice Guidelines in Oncology, Version 1. 2004
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
J Natl Cancer Inst
Alcohol and cancer
Cancer Res
Adenocarcinoma of the esophagusRole of obesity and diet
J Natl Cancer Inst
Consumption of nitrate, nitrite, and nitrosodimethylamine and the risk of upper aerodigestive tract cancer
Cancer Epidemiol Biomarkers Prev
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia
J Natl Cancer Inst
Esophageal cancer
Cancer statistics, 2003
CA Cancer J Clin
Analysis of the role of adjuvant chemotherapy for invasive carcinoma of the esophagus
Am J Clin Oncol
Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junctionA meta-analysis of randomized clinical trials
Ann Surg Oncol
Treatment of advanced esophageal cancer
Cancer
Experience with cisplatin in treatment regimens for esophageal cancer
Semin Oncol
Contributions of chemotherapy in the treatment of carcinoma of the esophagusResults and commentary
Semin Oncol
Paclitaxel in the treatment of carcinoma of the esophagus
Semin Oncol
Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus
Invest New Drugs
A late phase II study of docetaxel in patients with gastric cancer
Proc Am Soc Clin Oncol
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapyThe Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
Med Oncol
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF). A phase II trial
Am J Clin Oncol
Docetaxel (Taxotere) in advanced gastric cancerResults of a phase II clinical trial
Br J Cancer
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
Cancer Chemother Pharmacol
Phase I study of gemcitabine, docetaxel and carboplatin triple drug combination (GDC), with & without filgrastim (G-CSF) support, in patients with advanced non-hematological malignancies
Proc Am Soc Clin Oncol
Cited by (0)
Supported by Aventis Pharmaceuticals, Bridgewater, NJ.
Dr Rigas has received research grant support from Abbott, Amgen, Aventis, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Ligand, Merck, Ortho Biotech, OSI, Pfizer, and Roche; he is a consultant for Amgen, Bayer, GlaxoSmithKline, and Ligand. Dr Dragnev has received research grant support from Amgen, Abbott, Genentech and Ligand.